Ascentage Pharma Announces Relocation of Principal Place of Business in Hong Kong

On April 1, 2026, Ascentage Pharma Group International, a clinical-stage biotechnology company, filed a Form 6-K with the SEC announcing a change to its principal place of business in Hong Kong. Effective immediately, the Company\'s Hong Kong office has relocated to Unit 906, 9/F., Haleson Building, 1 Jubilee Street, Central, Hong Kong. The announcement was authorized by Dr. Dajun Yang, Chairman and Chief Executive Officer. This filing is administrative in nature and does not impact the company\'s clinical operations, financial standing, or ongoing research and development activities. The company continues to maintain its principal executive offices in Suzhou, Jiangsu, China. No other material changes to the company\'s board of directors or executive leadership were reported in this specific announcement.